Synairgen Plc of the UK has outlicensed an experimental compound for severe asthma to AstraZeneca Plc for an upfront fee of $7.25 million and potential development, regulatory and commercial milestones of up to $225 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
